Authors' recommendations: Description of Technology: Sacubitril-valsartan is made up of sacubitril, which is a neprilysin inhibitor, and valsartan, which is an angiotensin receptor blocker (ARB). The drug is commonly referred to as ARNI (dual-acting angiotensin receptor neprilysin inhibitor). Neprilysin and angiotensin both play a role in stimulating mechanisms such as vasoconstriction and sodium retention, which contribute to the pathophysiology of heart failure. Sacubitril-valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (New York Heart Association [NYHA] class II-IV) and reduced ejection fraction. It is usually administered in conjunction with other heart failure therapies in place of an angiotensinconverting enzyme (ACE) inhibitor or other ARBs. Patient Population: Sacubitril-valsartan is indicated for patients with chronic heart failure (NYHA class II-IV) and reduced ejection fraction. Sacubitril-valsartan should not be used by pregnant women, patients with an allergy to any of the components that make up the drug, or patients who have a history of angioedema associated with ACE inhibitors or ARB medications.

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=36426

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2014 Winifred S. Hayes, Inc